305 related articles for article (PubMed ID: 21502381)
1. Pilot pharmacokinetic and dosimetric studies of (18)F-FPPRGD2: a PET radiopharmaceutical agent for imaging α(v)β(3) integrin levels.
Mittra ES; Goris ML; Iagaru AH; Kardan A; Burton L; Berganos R; Chang E; Liu S; Shen B; Chin FT; Chen X; Gambhir SS
Radiology; 2011 Jul; 260(1):182-91. PubMed ID: 21502381
[TBL] [Abstract][Full Text] [Related]
2. (18)F-FPPRGD2 PET/CT: pilot phase evaluation of breast cancer patients.
Iagaru A; Mosci C; Shen B; Chin FT; Mittra E; Telli ML; Gambhir SS
Radiology; 2014 Nov; 273(2):549-59. PubMed ID: 25033190
[TBL] [Abstract][Full Text] [Related]
3. Pilot study of FPPRGD2 for imaging α(v)β(3) integrin--how integral are integrins?
Choyke PL
Radiology; 2011 Jul; 260(1):1-2. PubMed ID: 21697304
[TBL] [Abstract][Full Text] [Related]
4. Biodistribution and radiation dosimetry of the integrin marker 18F-RGD-K5 determined from whole-body PET/CT in monkeys and humans.
Doss M; Kolb HC; Zhang JJ; Bélanger MJ; Stubbs JB; Stabin MG; Hostetler ED; Alpaugh RK; von Mehren M; Walsh JC; Haka M; Mocharla VP; Yu JQ
J Nucl Med; 2012 May; 53(5):787-95. PubMed ID: 22499613
[TBL] [Abstract][Full Text] [Related]
5. Biodistribution of the ¹⁸F-FPPRGD₂ PET radiopharmaceutical in cancer patients: an atlas of SUV measurements.
Minamimoto R; Jamali M; Barkhodari A; Mosci C; Mittra E; Shen B; Chin F; Gambhir SS; Iagaru A
Eur J Nucl Med Mol Imaging; 2015 Nov; 42(12):1850-8. PubMed ID: 26062933
[TBL] [Abstract][Full Text] [Related]
6. microPET imaging of glioma integrin {alpha}v{beta}3 expression using (64)Cu-labeled tetrameric RGD peptide.
Wu Y; Zhang X; Xiong Z; Cheng Z; Fisher DR; Liu S; Gambhir SS; Chen X
J Nucl Med; 2005 Oct; 46(10):1707-18. PubMed ID: 16204722
[TBL] [Abstract][Full Text] [Related]
7. Glioblastoma Multiforme Recurrence: An Exploratory Study of (18)F FPPRGD2 PET/CT.
Iagaru A; Mosci C; Mittra E; Zaharchuk G; Fischbein N; Harsh G; Li G; Nagpal S; Recht L; Gambhir SS
Radiology; 2015 Nov; 277(2):497-506. PubMed ID: 25965900
[TBL] [Abstract][Full Text] [Related]
8. Pegylated Arg-Gly-Asp peptide: 64Cu labeling and PET imaging of brain tumor alphavbeta3-integrin expression.
Chen X; Hou Y; Tohme M; Park R; Khankaldyyan V; Gonzales-Gomez I; Bading JR; Laug WE; Conti PS
J Nucl Med; 2004 Oct; 45(10):1776-83. PubMed ID: 15471848
[TBL] [Abstract][Full Text] [Related]
9. Clinical Translation of a Dual Integrin αvβ3- and Gastrin-Releasing Peptide Receptor-Targeting PET Radiotracer, 68Ga-BBN-RGD.
Zhang J; Niu G; Lang L; Li F; Fan X; Yan X; Yao S; Yan W; Huo L; Chen L; Li Z; Zhu Z; Chen X
J Nucl Med; 2017 Feb; 58(2):228-234. PubMed ID: 27493267
[TBL] [Abstract][Full Text] [Related]
10. [(68)Ga]NODAGA-RGD - Metabolic stability, biodistribution, and dosimetry data from patients with hepatocellular carcinoma and liver cirrhosis.
Haubner R; Finkenstedt A; Stegmayr A; Rangger C; Decristoforo C; Zoller H; Virgolini IJ
Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):2005-13. PubMed ID: 27164900
[TBL] [Abstract][Full Text] [Related]
11. 68Ga-NODAGA-RGDyK for αvβ3 integrin PET imaging. Preclinical investigation and dosimetry.
Buchegger F; Viertl D; Baechler S; Dunet V; Kosinski M; Poitry-Yamate C; Rüegg C; Prior JO
Nuklearmedizin; 2011; 50(6):225-33. PubMed ID: 21989840
[TBL] [Abstract][Full Text] [Related]
12. 18F-ICMT-11, a caspase-3-specific PET tracer for apoptosis: biodistribution and radiation dosimetry.
Challapalli A; Kenny LM; Hallett WA; Kozlowski K; Tomasi G; Gudi M; Al-Nahhas A; Coombes RC; Aboagye EO
J Nucl Med; 2013 Sep; 54(9):1551-6. PubMed ID: 23949910
[TBL] [Abstract][Full Text] [Related]
13. Phase I, first-in-human study of BMS747158, a novel 18F-labeled tracer for myocardial perfusion PET: dosimetry, biodistribution, safety, and imaging characteristics after a single injection at rest.
Maddahi J; Czernin J; Lazewatsky J; Huang SC; Dahlbom M; Schelbert H; Sparks R; Ehlgen A; Crane P; Zhu Q; Devine M; Phelps M
J Nucl Med; 2011 Sep; 52(9):1490-8. PubMed ID: 21849402
[TBL] [Abstract][Full Text] [Related]
14. 18F-Fluorothymidine radiation dosimetry in human PET imaging studies.
Vesselle H; Grierson J; Peterson LM; Muzi M; Mankoff DA; Krohn KA
J Nucl Med; 2003 Sep; 44(9):1482-8. PubMed ID: 12960196
[TBL] [Abstract][Full Text] [Related]
15. Safety, Dosimetry, and Tumor Detection Ability of
Skovgaard D; Persson M; Brandt-Larsen M; Christensen C; Madsen J; Klausen TL; Holm S; Andersen FL; Loft A; Berthelsen AK; Pappot H; Brasso K; Kroman N; Højgaard L; Kjaer A
J Nucl Med; 2017 Mar; 58(3):379-386. PubMed ID: 27609788
[TBL] [Abstract][Full Text] [Related]
16. Whole-body radiation dosimetry of 2-[18F]Fluoro-A-85380 in human PET imaging studies.
Obrzut SL; Koren AO; Mandelkern MA; Brody AL; Hoh CK; London ED
Nucl Med Biol; 2005 Nov; 32(8):869-74. PubMed ID: 16253812
[TBL] [Abstract][Full Text] [Related]
17. (68)Ga-labeled multimeric RGD peptides for microPET imaging of integrin alpha(v)beta (3) expression.
Li ZB; Chen K; Chen X
Eur J Nucl Med Mol Imaging; 2008 Jun; 35(6):1100-8. PubMed ID: 18204838
[TBL] [Abstract][Full Text] [Related]
18. Biodistribution and radiation dosimetry of deuterium-substituted 18F-fluoromethyl-[1, 2-2H4]choline in healthy volunteers.
Challapalli A; Sharma R; Hallett WA; Kozlowski K; Carroll L; Brickute D; Twyman F; Al-Nahhas A; Aboagye EO
J Nucl Med; 2014 Feb; 55(2):256-63. PubMed ID: 24492392
[TBL] [Abstract][Full Text] [Related]
19. Imaging integrin alpha-v-beta-3 expression in tumors with an 18F-labeled dimeric RGD peptide.
Dijkgraaf I; Terry SY; McBride WJ; Goldenberg DM; Laverman P; Franssen GM; Oyen WJ; Boerman OC
Contrast Media Mol Imaging; 2013; 8(3):238-45. PubMed ID: 23606427
[TBL] [Abstract][Full Text] [Related]
20. First-in-Humans Trial of Dasatinib-Derivative Tracer for Tumor Kinase-Targeted PET.
Krebs S; Veach DR; Carter LM; Grkovski M; Fornier M; Mauro MJ; Voss MH; Danila DC; Burnazi E; Null M; Staton K; Pressl C; Beattie BJ; Zanzonico P; Weber WA; Lyashchenko SK; Lewis JS; Larson SM; Dunphy MPS
J Nucl Med; 2020 Nov; 61(11):1580-1587. PubMed ID: 32169913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
